Tolerability of XXXX in @entity1 with metastatic castration-resistant @entity263 progressing after @entity1205 and @entity15512 : a single-institution experience.

@entity1 @entity137 @entity263 @entity15512 @entity5 @entity229 @entity294 @entity1395 @entity1398 @entity8358 @entity15513 @entity1205
UNASSIGNED: Both @entity15512 (AA) and @entity15513 ( @entity8358 ) have been shown to prolong survival in @entity1 with metastatic castration-resistant @entity263 (mCRPC) progressing during or after @entity1205 (D). Although no standard sequencing has been established as yet, @entity8358 has recently been proven to be active after AA. However, to date, few data are available on its safety in this setting. Therefore, the primary endpoint of this study was to investigate @entity8358 tolerability in mCRPC @entity1 treated previously with D and AA. From April 2011 to the present, 43 mCRPC @entity1 received AA after D at our institution. Of these, 22 @entity1 were subsequently treated with @entity8358 and were evaluable for @entity137 in the present retrospective study. @entity8358 was administered at a dose of 25   mg/m plus 10   mg oral @entity229 every 3 weeks. Adverse events (AEs) were reported using the NCI CTCAE (National @entity5 Institute Common Terminology Criteria for Adverse Events) version 3.0. Despite the advanced stage of disease and frailty of our study population, there were no unexpected side effects. The most common AEs were hematologic. @entity1398 was observed in nine (40.9%) @entity1 and of grade>= 3 in six (27.2%). No @entity1398 occurred. The most common nonhematologic AEs were @entity294 and @entity1395 , reported in eight (36.3%) and in five (22.7%) @entity1 , respectively. In this setting, @entity8358 @entity137 seems to be manageable and comparable with second-line @entity8358 . Therefore, our results seem to support the safety of @entity8358 as a third-line treatment for mCRPC @entity1 .
